{"id":"radiotherapy-and-pcv-chemotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (anemia, thrombocytopenia, leukopenia)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Radiation dermatitis"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Secondary malignancy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Radiotherapy delivers high-energy radiation to tumor sites, causing direct DNA damage and cell death. PCV chemotherapy is a multi-agent regimen where procarbazine and lomustine are alkylating agents that cross-link DNA, and vincristine is a vinca alkaloid that disrupts microtubule formation. Together, these modalities work synergistically to maximize tumor cell killing while attempting to preserve normal tissue.","oneSentence":"This combination uses ionizing radiation to destroy tumor cells directly while chemotherapy with procarbazine, lomustine, and vincristine (PCV) enhances cell death through DNA damage and mitotic inhibition.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:31:11.238Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glioblastoma or high-grade glioma (Phase 3 trial context)"}]},"trialDetails":[{"nctId":"NCT05331521","phase":"PHASE3","title":"A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas).","status":"RECRUITING","sponsor":"University Hospital Heidelberg","startDate":"2021-04-07","conditions":"Oligodendroglioma","enrollment":406},{"nctId":"NCT04702581","phase":"PHASE3","title":"A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2021-12-07","conditions":"Oligodendroglioma, Low-grade Oligodendroglioma, 1p19q Codeletion","enrollment":280},{"nctId":"NCT02444000","phase":"PHASE3","title":"gliomasPCV Only in 1p/19q Codeleted Anaplastic Gliomas","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-09-22","conditions":"Anaplastic Gliomas With 1p/19q Codeletion","enrollment":280},{"nctId":"NCT00887146","phase":"PHASE3","title":"Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2009-09","conditions":"Brain and Central Nervous System Tumors","enrollment":305},{"nctId":"NCT07104266","phase":"PHASE2","title":"Triple Negative Breast Cancer and Celecoxib. Pilot Study","status":"RECRUITING","sponsor":"Université de Sherbrooke","startDate":"2025-08-04","conditions":"Triple-Negative Breast Cancer","enrollment":30},{"nctId":"NCT00003375","phase":"PHASE2, PHASE3","title":"Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"1998-10","conditions":"Brain and Central Nervous System Tumors","enrollment":370},{"nctId":"NCT01678352","phase":"EARLY_PHASE1","title":"Imiquimod and Tumor Lysate Vaccine Immunotherapy in Adults With High Risk or Recurrent Grade II Gliomas","status":"COMPLETED","sponsor":"Frank Lieberman","startDate":"2012-10","conditions":"High Risk WHO Grade II Glioma, Recurrent/Post-Chemotherapy WHO Grade II Glioma","enrollment":19},{"nctId":"NCT02297230","phase":"PHASE1, PHASE2","title":"Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics","status":"TERMINATED","sponsor":"NYU Langone Health","startDate":"2002-06","conditions":"Breast Cancer","enrollment":44},{"nctId":"NCT01786018","phase":"PHASE2","title":"Thiotepa, Busulfan and Fludarabin for pt With Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas","status":"UNKNOWN","sponsor":"Azienda Ospedaliera San Giovanni Battista","startDate":"2013-02","conditions":"B-cell Lymphoma Refractory","enrollment":42},{"nctId":"NCT01339988","phase":"PHASE4","title":"Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT)","status":"UNKNOWN","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2011-06","conditions":"Acute Leukemias, Chronic Leukemias, Myelodysplastic Syndrome","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":93,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Radiotherapy and PCV chemotherapy","genericName":"Radiotherapy and PCV chemotherapy","companyName":"Hospices Civils de Lyon","companyId":"hospices-civils-de-lyon","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses ionizing radiation to destroy tumor cells directly while chemotherapy with procarbazine, lomustine, and vincristine (PCV) enhances cell death through DNA damage and mitotic inhibition. Used for Glioblastoma or high-grade glioma (Phase 3 trial context).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}